

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

OUTSTANDING DEBT FROM BIOLIDICS

The board of directors (the "**Board**" or the "**Directors**") of Clearbridge Health Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the announcements of the Company dated 27 March 2020, 3 April 2020, 26 May 2020, 24 December 2021, 24 June 2022, 23 September 2022, 28 February 2023, 10 March 2023, 22 September 2023 and 4 October 2023 (the "**Announcements**"). All capitalised terms used and not defined in this announcement shall have the same meanings ascribed to them in the Announcements. In particular, in the Company's announcement dated 4 October 2023, it noted that Biolidics had entered into a term sheet with Mr Zhu Hua in relation to the proposed subscription by the Investor of 230,769,231 new ordinary shares in the issued share capital of Biolidics. The Company understands that the proceeds from the Proposed Subscription was intended to repay the Outstanding Debt of S\$2,138,750.

The Company refers to the announcement by Biolidics dated 21 November 2023 ("**New Subscription Announcement**"), pursuant to which it was announced that as the approval of Biolidics' shareholders for the Proposed Subscription was not obtained at the extraordinary general meeting held on 21 November 2023, the subscription agreement dated 12 October 2023 entered into between Biolidics and the Investor ("**12 October Agreement**") has been terminated and the Proposed Subscription was not completed. In the New Subscription Announcement, Biolidics also announced that it has entered into a new subscription agreement with the Investor ("**New Subscription Agreement**") pursuant to which Biolidics shall issue and allot 98,500,000 new ordinary shares in the issued share capital of Biolidics ("**Subscription Shares**") to the Investor at a subscription price of S\$0.0119 per Subscription Share, for an aggregate subscription amount of S\$1,172,150. Based on the New Subscription Announcement, the Subscription Shares will be allotted and issued pursuant to the general mandate from Biolidics' shareholders at the annual general meeting of Biolidics held on 28 April 2023 for the issuance of shares.

The Company wishes to announce that it has, on 21 November 2023, received a letter from Biolidics stating that it has negotiated for and finalised plans for an alternative source of funding to repay the Outstanding Debt ("**Alternative Funding**"), which the Company now understands to be the New Subscription Agreement. Biolidics has therefore requested for an extension of time for the repayment of the Outstanding Debt to 23 December 2023 ("**Proposal**"). This is also set out in the New Subscription Announcement.

The Company is considering the Proposal and considering its options with respect to the Outstanding Debt. The Company will provide further updates through its announcements in due course.

As at the date of this announcement, save for Mr Chen Johnson, the Non-Executive and Non-Independent Chairman of the Company, who owns 0.49% of Biolidics, none of the Directors has any interest, direct or indirect, in any matters set out in this announcement, other than through their respective shareholdings in the Company. As at the date of this announcement, based on publicly

available information and as far as the Directors are aware, the controlling shareholders of the Company do not have any interest, direct or indirect, in any matters set out in this announcement, other than through their respective shareholdings in the Company.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

22 November 2023

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*